[HTML][HTML] Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in …
H Zhao, Y Fan, S Ma, X Song, B Han, Y Cheng… - Journal of Thoracic …, 2015 - Elsevier
Background The results of the Iressa in NSCLC for maintenance study (NCT00770588; C-
TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with …
TONG 0804), which compared gefitinib and placebo as maintenance therapy in patients with …
[HTML][HTML] EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR …
M Varella-Garcia, T Mitsudomi, Y Yatabe… - Journal of Thoracic …, 2009 - Elsevier
Background Sensitivity to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) and frequency of activation mutations in EGFR is lower in Caucasian than Asian non …
(TKIs) and frequency of activation mutations in EGFR is lower in Caucasian than Asian non …
Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)
FR Hirsch, LV Sequist, I Gore, M Mooradian, G Simon… - Cancer, 2018 - Wiley Online Library
BACKGROUND This is the first report of long‐term (> 10 years) safety, tolerability, and
survival data on patients with non–small cell lung cancer (NSCLC) who received treatment …
survival data on patients with non–small cell lung cancer (NSCLC) who received treatment …
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations
W Tang, X Li, X Xie, X Sun, J Liu, J Zhang, C Wang… - Lung Cancer, 2019 - Elsevier
Objectives Cisplatin-based chemotherapy as an adjuvant therapy for resected non-small cell
lung cancer (NSCLC) has reached its plateau, and it is limited by a high risk of recurrence …
lung cancer (NSCLC) has reached its plateau, and it is limited by a high risk of recurrence …
Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment
BACKGROUND: A prognostic model based on clinical parameters for nonsmall cell lung
cancer (NSCLC) patients treated with gefitinib (250 mg/day) as a salvage therapy was …
cancer (NSCLC) patients treated with gefitinib (250 mg/day) as a salvage therapy was …
Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer
KH Lim, MJ Huang, HC Liu, HT Kuo, CY Tzen… - Medical Oncology, 2007 - Springer
Purpose To investigate the prognostic value of epidermal growth factor receptor (EGFR)
mutations in a series of Taiwanese patients with primary resected lung adenocarcinomas …
mutations in a series of Taiwanese patients with primary resected lung adenocarcinomas …
[HTML][HTML] Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
YY Janjigian, BJ Park, MF Zakowski, M Ladanyi… - Journal of Thoracic …, 2011 - Elsevier
Background: Patients with stage IV lung adenocarcinoma and epidermal growth factor
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …
Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy
MG Kris, W Pao, MF Zakowski, M Ladanyi… - Journal of Clinical …, 2006 - ascopubs.org
7021 Background: Induction therapy provides a unique opportunity for the objective
assessment of therapies in patients with NSCLC to facilitate care and advance research. We …
assessment of therapies in patients with NSCLC to facilitate care and advance research. We …
Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
Y Tomizawa, Y Fujita, A Tamura, M Shirai, S Shibata… - Lung Cancer, 2010 - Elsevier
PURPOSE: We investigated the efficacy of gefitinib re-challenge for the patients who
responded to initial treatment with gefitinib and acquired resistance to gefitinib thereafter …
responded to initial treatment with gefitinib and acquired resistance to gefitinib thereafter …